NasdaqGS:NVAXBiotechs
Why Novavax (NVAX) Is Down 7.0% After Crushing Q4 Revenue And Earnings Forecasts - And What's Next
In its most recent reported quarter, Novavax posted Q4 revenue growth of 66.6% year over year and exceeded analysts’ estimates for both revenue and EPS, ranking as the strongest performer in the therapeutics sector by revenue growth.
An interesting twist is that, despite these very strong fundamentals relative to peers and forecasts, investor expectations appear to have been set even higher than consensus.
Next, we’ll examine how Novavax’s faster-than-peer revenue growth and earnings beat...